At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 70 enrolled
Drug / intervention
Albendazole IP 400 mg +1 moredrug
Likely dose
Albendazole IP 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Balanced, Randomized, Two-Treatment, Four-Period, Two-Sequence, Single Oral Dose, Full Replicate Crossover, Bioequivalence Study of Albendazole Tablets IP 400 mg of Biddle Sawyer Limited (GSK Group Company) With Albendazole Tablets 400 mg of Glaxo SmithKline Consumer Healthcare, South Africa (PTY) Ltd in Healthy, Adult Participants Under Fed Condition
In Brief
A Phase 1 clinical trial evaluating Albendazole IP 400 mg and Albendazole 400 mg for Intestinal Diseases. Completed, enrolled 70 participants across 1 site.
Detailed Summary
The goal of this study is to compare two formulations of Albendazole of the same dose in healthy adult participants. Researchers will compare the extent and rate to which the drug is absorbed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntestinal Diseases
CountriesIndia
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
Enrollment StartAug 2023
Primary CompletionSep 2023
First PostedJan 2024
TodayJul 2026
First PostedJan 11, 2024
Enrollment StartAug 21, 2023
Primary CompletionSep 12, 2023
TodayJul 2, 2026
Enrollment to primary: 21 daysPosted 2.5 years ago
Interventions
Albendazole IP 400 mgdrug
Albendazole IP 400 mg tablets will be administered under fed conditions
Albendazole 400 mgdrug
Albendazole 400 mg tablets will be administered under fed conditions